Sugi Predict

Sugi Predict / Compounds / SCHEMBL1647703

SCHEMBL1647703

SCHEMBL1647703

CC(C)(C)[Si](C)(C)OCCNc1cccc(N2CCN(c3ccc(N)cc3)CC2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.37
▸ MAPT P10636 4/20 0.36
▸ GFER P55789 4/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ GAA P10253 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ RAD52 P43351 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.35
▸ ADRA2C P18825 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ PTK2B Q14289 1/20 0.35
▸ ESR2 Q92731 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ ALOX12 P18054 1/20 0.34
▸ KCNH2 Q12809 1/20 0.33
▸ HTR1A P08908 4/20 0.33
▸ TLR9 Q9NR96 1/20 0.33
▸ DRD2 P14416 3/20 0.33
▸ HTR2A P28223 3/20 0.33
▸ HTR7 P34969 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1648726 0.83 PDE10A (0.38) HSD11B1MAPTGFERKDM4EGAA
SCHEMBL1646386 0.80 MAPT (0.35) HSD11B1MAPTGFERKDM4EGAA
SCHEMBL6027182 0.72 NPSR1 (0.41) KDM4EALDH1A1KMT2ALMNA
SCHEMBL1644705 0.71 ALDH1A1 (0.38) MAPTKDM4EGAASMN1; SMN2ALDH1A1
SCHEMBL1023793 0.71 APP (0.37) MAPTGAARAD52
SCHEMBL1126465 0.68 HTR3E (0.63) HSD11B1MAPTGFERKDM4EGAA
SCHEMBL942671 0.68 MAPT (0.51) HSD11B1MAPTGFERKDM4EGAA
SCHEMBL22495410 0.68 MAPT (0.47) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL25327767 0.67 MAPT (0.41) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL6418699 0.67 ADRA2C (0.51) MAPTSMN1; SMN2ALDH1A1ADRA2CKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 — — US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 — — US disclosed
EP-2303329-A1 ANTIFUNGAL COMBINATION THERAPY F2G Limited (GB) 2011-04-06 — — EP disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 — — US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 — — WO disclosed
EP-2097413-A1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G Limited (GB) 2009-09-09 — — EP disclosed
WO-2008062182-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2008-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 HSD11B1 454/4885MAPT 1771/4885GFER 3245/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 HSD11B1 1887/4885MAPT 2950/4885GFER 1317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.